Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Withdrawn 1Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Melanoma 11Triple Negative Breast Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Neoplasms 7Head and Neck Neoplasms 7Multiple Myeloma 6Carcinoma, Transitional Cell 6Carcinoma, Renal Cell 6Pancreatic Neoplasms 5Lung Neoplasms 4Recurrence 3Prostatic Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Sarcoma 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Kidney Neoplasms 2Inflammatory Breast Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Urothelial Cancer 1Thyroid Neoplasms 1Subcutaneous panniculitis-like T-cell lymphoma 1Spinocerebellar Degenerations 1

Interventions

pembrolizumab 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Clear-cell metastatic renal cell carcinoma × pembrolizumab × Clear all
NCT06361810 2025-08-19

PSMA Therapy and Immunotherapy in Kidney Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Withdrawn
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡